DE69330387D1 - Amantadine und verwandte Verbindungen zur Anwendung zur Behandlung von Neuropathie - Google Patents

Amantadine und verwandte Verbindungen zur Anwendung zur Behandlung von Neuropathie

Info

Publication number
DE69330387D1
DE69330387D1 DE69330387T DE69330387T DE69330387D1 DE 69330387 D1 DE69330387 D1 DE 69330387D1 DE 69330387 T DE69330387 T DE 69330387T DE 69330387 T DE69330387 T DE 69330387T DE 69330387 D1 DE69330387 D1 DE 69330387D1
Authority
DE
Germany
Prior art keywords
amantadine
neuropathy
mammal
treatment
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69330387T
Other languages
English (en)
Other versions
DE69330387T2 (de
Inventor
A Lipton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cincinnati Childrens Hospital Medical Center
Original Assignee
Cincinnati Childrens Hospital Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cincinnati Childrens Hospital Medical Center filed Critical Cincinnati Childrens Hospital Medical Center
Publication of DE69330387D1 publication Critical patent/DE69330387D1/de
Application granted granted Critical
Publication of DE69330387T2 publication Critical patent/DE69330387T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
DE69330387T 1992-09-03 1993-09-03 Amantadine und verwandte Verbindungen zur Anwendung zur Behandlung von Neuropathie Expired - Lifetime DE69330387T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/939,824 US5334618A (en) 1991-04-04 1992-09-03 Method of preventing NMDA receptor-mediated neuronal damage
PCT/US1993/008344 WO1994005275A1 (en) 1992-09-03 1993-09-03 Method of preventing nmda receptor-mediated neuronal damage

Publications (2)

Publication Number Publication Date
DE69330387D1 true DE69330387D1 (de) 2001-08-02
DE69330387T2 DE69330387T2 (de) 2002-05-16

Family

ID=25473800

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69330387T Expired - Lifetime DE69330387T2 (de) 1992-09-03 1993-09-03 Amantadine und verwandte Verbindungen zur Anwendung zur Behandlung von Neuropathie

Country Status (12)

Country Link
US (1) US5334618A (de)
EP (1) EP0660707B1 (de)
JP (2) JPH08501297A (de)
AT (1) ATE202474T1 (de)
AU (1) AU4847693A (de)
CA (1) CA2143752C (de)
DE (1) DE69330387T2 (de)
DK (1) DK0660707T3 (de)
ES (1) ES2159528T3 (de)
GR (1) GR3036657T3 (de)
PT (1) PT660707E (de)
WO (1) WO1994005275A1 (de)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2714828B1 (fr) * 1994-01-12 1996-02-02 Rhone Poulenc Rorer Sa Application du riluzole dans le traitement des maladies mitochondriales.
US6025369A (en) * 1996-05-03 2000-02-15 The Board Of Regents Of The University Nebraska N-methyl-D-aspartate (NMDA) receptor blockers for the prevention of atherosclerosis
US6242456B1 (en) * 1998-03-09 2001-06-05 Trustees Of Tufts College Treatment of stereotypic, self-injurious and compulsive behaviors in man and animals using antagonists of NMDA receptors
US20070197651A1 (en) * 1998-03-09 2007-08-23 Tufts University Treatment of stereotypic, self-injurious and compulsive behaviors in man and animals using antagonists of NMDA receptors
US20060167114A1 (en) * 1998-03-09 2006-07-27 Louis Shuster Treatment of stereotypic, self-injurious and compulsive behaviors in man and animals using antagonists of NMDA receptors
GB9901691D0 (en) * 1999-01-26 1999-03-17 Cerebrus Ltd Chemical compounds
US6444702B1 (en) 2000-02-22 2002-09-03 Neuromolecular, Inc. Aminoadamantane derivatives as therapeutic agents
EP1284729A4 (de) * 2000-04-13 2007-12-19 Mayo Foundation A-(beta)-42 senkende arzneimittel
EP1201234A3 (de) * 2000-09-21 2003-03-12 Tinnitus Forschungs- und Entwicklungs GmbH Behandlung von Erkrankungen mit Adamantan-derivaten
EP1190711A1 (de) * 2000-09-21 2002-03-27 Tinnitus Forschungs- und Entwicklungs GmbH Behandlung von Erkrankungen mit Adamantan-derivaten
EP1190708A1 (de) * 2000-09-21 2002-03-27 Tinnitus Forschungs- und Entwicklungs GmbH Medizinische Verwendung von Verbindungen
EP1852113A3 (de) * 2000-12-07 2008-03-12 Neuromolecular Inc. Verfahren zur Behandlung neuropsychiatrischer Erkrankungen mit NMDA-Rezeptorantagonisten
WO2002045710A1 (en) * 2000-12-07 2002-06-13 Neuromolecular Inc. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
US20040122090A1 (en) * 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
EP1420772A2 (de) * 2001-08-29 2004-05-26 Eucro European Contract Research GmbH & Co. KG Verwendung von beta-adrenozeptor-agonisten zur behandlung von neurodegenerativen erkrankungen
GB0202161D0 (en) * 2002-01-30 2002-03-20 Vernalis Res Ltd Chemical compounds V
AU2003298514A1 (en) * 2002-05-17 2004-05-04 Eisai Co., Ltd. Methods and compositions using cholinesterase inhibitors
US8557855B2 (en) * 2002-07-03 2013-10-15 Allergan, Inc. Methods of using ryanodine antagonists in treating neural injury
US20050148673A1 (en) * 2002-07-11 2005-07-07 Harbut Ronald E. Prolonged administration of NMDA antagonist and safener drug to alter neuropathic pain condition
US20040087658A1 (en) 2002-10-24 2004-05-06 Hans-Joerg Moebius Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors
WO2004071431A2 (en) * 2003-02-05 2004-08-26 Myriad Genetics, Inc. Method and composition for treating neurodegenerative disorders
US7521481B2 (en) * 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
AU2004251636B2 (en) * 2003-05-27 2006-11-09 Merz Pharma Gmbh & Co. Kgaa Combination of an NMDA receptor antagonist and a selective serotonin reuptake inhibitor for the treatment of depression and other mood disorders
AU2004311577A1 (en) * 2003-07-11 2005-07-21 Myriad Genetics, Inc. Pharmaceutical methods, dosing regimes and dosage forms for the treatment of Alzheimer's disease
AR046314A1 (es) 2003-11-05 2005-11-30 Merz Pharma Gmbh & Co Kgaa Composiciones que comprenden ciclohexilaminas y aminoadamantanos
UY28650A1 (es) * 2003-12-05 2005-02-28 Forest Laboratories Memantina para la prevencion o disminucion de la conducta suicida y para el tratamiento de la depresion mayor asociada con esta conducta
PL1703902T3 (pl) * 2004-01-05 2011-04-29 Merz Pharma Gmbh & Co Kgaa Memantyna do leczenia choroby Alzheimera o łagodnym do umiarkowanego stopniu zaawansowania
EP1715843A1 (de) * 2004-01-29 2006-11-02 Neuromolecular Inc. Kombination eines nmda-rezeptor-antagonisten und eines mao-hemmers oder eines gadph-hemmers zur behandlung von erkrankungen im zusammenhang mit dem zentralen nervensystem
TW200531680A (en) * 2004-03-03 2005-10-01 Merz Pharma Gmbh & Co Kgaa Therapy using 1-aminocyclohexane derivatives for the treatment of behavioral disorders associated with alzheimer's disease
US20070293538A1 (en) * 2004-04-13 2007-12-20 Myriad Genetics, Incorporated Pharmaceutical Composition And Methods For Treating Neurodegenerative Disorders
EP1765287A2 (de) 2004-06-17 2007-03-28 Merz Pharma GmbH & Co. KGaA Formulierungen für die sofortige freisetzung oraler memantin-darreichungsformen
AU2005265031A1 (en) * 2004-06-17 2006-01-26 Forest Laboratories, Inc. Modified release formulation of memantine
US20060002999A1 (en) 2004-06-17 2006-01-05 Forest Laboratories, Inc. Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
TW200616608A (en) * 2004-07-09 2006-06-01 Forest Laboratories Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients
WO2006020852A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
BRPI0514303A (pt) * 2004-08-11 2008-06-10 Myriad Genetics Inc composição farmacêutica e método para tratar distúrbios neurodegenerativos
WO2006020850A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
CN100351225C (zh) * 2004-10-28 2007-11-28 中国医学科学院医药生物技术研究所 一组金刚烷胺类衍生物及其合成方法和作为神经元损伤保护剂的应用
EP2343057A1 (de) 2004-11-23 2011-07-13 Neuromolecular Pharmaceuticals, Inc Verfahren und Zusammensetzung zur Verabreichung eines NMDA-Rezeptorantagonisten an eine Person
US7619007B2 (en) * 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
CA2588296A1 (en) 2004-11-24 2006-06-01 Neuromolecular Pharmaceuticals, Inc. Composition comprising an nmda receptor antagonist and levodopa and use thereof for treating neurological disease
US20060205822A1 (en) * 2004-12-22 2006-09-14 Forest Laboratories, Inc. 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect
DK1874282T3 (da) 2005-04-06 2010-10-25 Adamas Pharmaceuticals Inc Fremgangsmåder og præparater til behandling af CNS lidelser
US20080009546A1 (en) * 2005-05-06 2008-01-10 Chevron U.S.A. Inc. Diamondoid derivatives possessing therapeutic activity in the treatment of neurologic disorders
CA2607600A1 (en) * 2005-06-16 2006-12-28 Forest Laboratories, Inc. Modified and immediate release memantine bead formulation
WO2008005534A2 (en) * 2006-07-06 2008-01-10 Forest Laboratories, Inc. Orally dissolving formulations of memantine
WO2008006099A2 (en) * 2006-07-07 2008-01-10 Myriad Genetics, Inc. Treatment of psychiatric disorders
WO2009151498A2 (en) * 2008-03-28 2009-12-17 Forest Laboratories Holdings Limited Memantine formulations
EP2138173A1 (de) 2008-06-26 2009-12-30 Merz Pharma GmbH & Co.KGaA Pharmazeutische Zusammensetzungen mit Aminoadamantan-Derivaten
US8741343B2 (en) 2009-12-02 2014-06-03 Adamas Pharmaceuticals, Inc. Method of administering amantadine prior to a sleep period
TWI481401B (zh) 2010-01-27 2015-04-21 Takeda Pharmaceutical 藥劑
JP5562716B2 (ja) * 2010-05-12 2014-07-30 花王株式会社 電位依存性カチオンチャネル抑制剤
US10154971B2 (en) 2013-06-17 2018-12-18 Adamas Pharma, Llc Methods of administering amantadine
CA3081604A1 (en) * 2017-11-22 2019-05-31 Panorama Research, Inc. Aminoadamantyl nitrate compounds and their use to treat cns disorders

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3328251A (en) * 1965-12-30 1967-06-27 Du Pont Pharmaceutical compositions and methods utilizing 2-aminoadamantane and its derivatives
US3391142A (en) * 1966-02-09 1968-07-02 Lilly Co Eli Adamantyl secondary amines
US3456057A (en) * 1968-06-28 1969-07-15 Du Pont Pharmaceutical compositions and methods utilizing 3-aminotricyclo(4.3.1.1**3.8)undecanes
ES413944A1 (es) * 1972-04-20 1976-06-01 Merz & Co Procedimiento para la preparacion de compuestos de adamen- tano trisustituidos en las posiciones 1,3,5.
IL53441A0 (en) * 1977-11-22 1978-01-31 Teva Pharma Methyladamantyl hydrazines their preparation and pharmaceutical compositions containing them
US4148896A (en) * 1978-02-22 1979-04-10 E. I. Du Pont De Nemours And Company Antidepressant combination
US4351847A (en) * 1981-06-26 1982-09-28 Pennwalt Corporation Antiviral alpha, alpha-dialkyl adamantylethylamines
US4806543A (en) * 1986-11-25 1989-02-21 Board Of Trustees Of The Leland Stanford Junior University Method and compositions for reducing neurotoxic injury
US4837218A (en) * 1987-10-23 1989-06-06 Washington University Alkylated bicycloalkaneamines for treatment of neurotoxic injury
EP0392059B1 (de) * 1989-04-14 1993-09-15 Merz & Co. GmbH & Co. Verwendung von Adamantan-Derivaten zur Prävention und Behandlung der cerebralen Ischämie
DE3940410A1 (de) * 1989-12-04 1991-06-06 Schering Ag Neue verwendung von nmda-rezeptor-antagonisten
WO1992017168A1 (en) * 1991-04-04 1992-10-15 The Children's Medical Center Corporation Method of preventing nmda receptor-mediated neuronal damage
US5124319A (en) * 1991-10-11 1992-06-23 American Home Products Corporation Benzimidazole phosphono-amino acids

Also Published As

Publication number Publication date
DK0660707T3 (da) 2001-10-01
PT660707E (pt) 2001-11-30
ES2159528T3 (es) 2001-10-16
JPH08501297A (ja) 1996-02-13
DE69330387T2 (de) 2002-05-16
CA2143752A1 (en) 1994-03-17
EP0660707A1 (de) 1995-07-05
ATE202474T1 (de) 2001-07-15
AU4847693A (en) 1994-03-29
JP2006077034A (ja) 2006-03-23
CA2143752C (en) 2008-11-18
US5334618A (en) 1994-08-02
WO1994005275A1 (en) 1994-03-17
EP0660707B1 (de) 2001-06-27
GR3036657T3 (en) 2001-12-31
EP0660707A4 (de) 1998-05-13

Similar Documents

Publication Publication Date Title
DE69330387T2 (de) Amantadine und verwandte Verbindungen zur Anwendung zur Behandlung von Neuropathie
DE69016667D1 (de) Stabilisierte komplexe bestehend aus stickoxyd/primäre amine zur verwendung als kardiovaskuläre wirkstoffe.
BG105711A (en) 3-azabicyclo[3.1.0]hexane derivatives as opiate receptors ligands
EA200000391A1 (ru) Производные тиенопиримидина и тиенопиридина, полезные в качестве противораковых агентов
ATE196252T1 (de) Behandlung von hornincontinenz durch verwendung von (s)-oxybutynin und (s)-desethyloxybutynin
NO914356D0 (no) Mono n-substituerte 1,4,7,10-tetraazacyklododecan-derivater
DE69610627T2 (de) Neuartige peptidderivate
PL289487A1 (en) Method of producing new aminophenol derivatives
DE69608804D1 (de) Di- und trivalente kleine moleküle als selektininhibitoren
ATE317912T1 (de) Verfahren zur herstellung von beta-lactamen
UA26403A (uk) Похідhі n-заміщеhого 4-феhіл-4-піперидиhкарбоксаміду та їх фармацевтичhо прийhятhі солі, що проявляють аhестезувальhу та аhальгезувальhу дію, спосіб їх одержаhhя та фармацевтичhа композиція
PL350568A1 (en) N-(2-phenyl-4-aminobutyl)-1-naphtamides as antagonists of neurokinin 1 receptors
DK0561846T3 (da) 4,5-dihydroxy- og 4,5,8-trihydroxy-9,10-dihydro-9,10-dioxo-2-anthracencarboxylsyre-dicarbonater og -urethaner med terapeutisk virkning
ATE170853T1 (de) Antitumorpräparate und verfahren zur behandlung
DE69132575T2 (de) Sampangin-derivate zur verwendung als antimykotische und antimykobakterielle wirkstoffe
ATE48759T1 (de) Behandlung von anfaellen und hierfuer nuetzliche pharmazeutische zusammensetzungen.
DE69526584D1 (de) Verwendung von immunosuppressiva zur behandlung der schizophrenie
CO4761039A1 (es) Mezclas fungicidas que contienen carbamatos y amidas de acido carboxilico
GR1001309B (el) Μεθοδος παρασκευης παραγωγου ενωσεως της διχλωροανιλινης.
DE69023006D1 (de) Verfahren zur behandlung von thrombocytopenie und dafür geeignete pharmazeutische zusammensetzungen.
DE3881703T2 (de) Behandlung zur verbesserung der eigenschaften von keratintextilmaterialien.
SE9404438D0 (sv) New process
ATE157665T1 (de) 9-amino-pyridazino 4',5' : 3,4>pyrrolo- 2,1- a>isochinoline und deren verwendung für die herstellung von pharmazeutischen zubereitungen
DE69333270D1 (de) Aminderivate von oxo- und hydroxy- substituierten kohlenwasserstoffen
ES8705847A1 (es) Procedimiento para preparar nuevos derivados de n-(2-hidro- xialquil)-aminoacidos

Legal Events

Date Code Title Description
8364 No opposition during term of opposition